Rakovina – Talk Bio

Actionable Insights Powered by AI

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

1 month ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

2 months ago talkbio0Tagged AI-discovered drugs, ATR, ATR/mTOR Inhibitors, Brain Neoplasms, CNS-penetrant, dual pathway inhibition, Enki generative AI, preclinical data, PTEN-deficient tumors, Rakovina, Society for Neuro-Oncology

Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition